Board Meeting Details

The Board of Directors meeting was held on 7 August 2026, commencing at 3:00 p.m. (IST) and concluding at 4:30 p.m. (IST). The meeting was previously intimated to the exchange via letter dated 1 August 2026.

Financial Results Overview

The company reported a net loss of ₹17.81 crore for the quarter ended 30 June 2026, compared to a net loss of ₹4.35 crore in the corresponding quarter of the previous year (30 June 2025).

Key Financial Figures (Quarter ended 30 June 2026)

  • Revenue from operations: ₹900.24 crore
  • Other income: ₹48.23 crore
  • Total revenue: ₹948.47 crore
  • Total expenses: ₹963.35 crore
  • Loss before tax: ₹14.88 crore
  • Tax expenses: ₹2.93 crore (Income-Tax of Earlier Year)
  • Net loss: ₹17.81 crore
  • Basic and diluted earnings per share: -₹0.23
  • Paid-up equity capital: ₹779.13 crore (face value ₹10 per share)

Comparative Financial Performance

| Particulars | 30-06-2026 (Unaudited) | 31-03-2026 (Audited) | 30-06-2025 (Unaudited) | 31-03-2026 (Audited) |

| Revenue from operations | ₹900.24 crore | ₹1139.93 crore | ₹1085.36 crore | ₹4747.27 crore |

| Other income | ₹48.23 crore | ₹7.66 crore | ₹9.48 crore | ₹34.04 crore |

| Total revenue | ₹948.47 crore | ₹1147.59 crore | ₹1094.84 crore | ₹4781.31 crore |

| Total expenses | ₹963.35 crore | ₹1081.73 crore | ₹1101.94 crore | ₹4432.69 crore |

| Profit/(Loss) before tax | -₹14.88 crore | ₹20.47 crore | -₹7.10 crore | ₹303.23 crore |

| Net profit/(loss) | -₹17.81 crore | ₹10.10 crore | -₹4.35 crore | ₹220.17 crore |

| Basic EPS | -₹0.23 | ₹0.13 | -₹0.06 | ₹2.92 |

Expense Breakdown (Quarter ended 30 June 2026)

  • Cost of material consumed: ₹13.51 crore
  • Purchase of stock in trade: ₹256.13 crore
  • Changes in inventories: ₹52.87 crore
  • Employee benefits expenses: ₹372.64 crore
  • Finance costs: ₹3.24 crore
  • Depreciation and amortization: ₹10.57 crore
  • Other expenses: ₹254.39 crore

Regulatory Compliance and Review

The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors. The statutory auditor, Shah Doshi Patel & Associates LLP (FRN: W101155), conducted a limited review as required under Regulation 33 of SEBI (LODR) Regulations, 2015, and issued an unmodified limited review report.

Accounting Standards

The company has adopted Indian Accounting Standards (Ind AS) with effect from 1 April 2017, and the financial results are prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013.

Business Segment

The company operates in a single pharmaceutical segment, and the financial results represent this single segment only.

Document Submission and Availability

This intimation was submitted to BSE Limited and is also being uploaded on the company's website at https://www.gujaratterce.in/financial-results/.